iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/w1BUZ5m
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Bharat Biotech's iNNOVACC: India's 1st intranasal vaccine to cost Rs 800 in private markets, Rs 325 for govt
https://ift.tt/hH0yiB2
No comments:
Post a Comment